Background {#Sec1}
==========

The prognosis of patients with metastatic colorectal cancer (mCRC) has been significantly improved by the use of several consecutive chemotherapy drugs.^[@CR1]^ First-line chemotherapy irinotecan, 5-fluorouracil (5FU) and bevacizumab became a standard of care in mCRC.^[@CR2],[@CR3]^ Due to the prolonged survival, up to 2--3 years under treatment, and in order to avoid heavy treatment burden and toxicity, chemotherapy-free intervals (CFI) were proposed in different studies with oxaliplatin- or irinotecan-based first-line induction chemotherapy (IC).^[@CR4]--[@CR6]^

A pooled analysis of several trials has shown that CFI did not impair overall survival (OS) and advocate for biomarker research to define a predictive factor.^[@CR7]^ Nevertheless, the predictive factors associated with a long duration of CFI remain poorly studied. On the other hand, early identification of patients who will have an early progression during IC is an important challenge in order to intensify front-line treatment. Previous recent large trials have reported prognostic factors for progression-free survival (PFS),^[@CR8]--[@CR10]^ but not for early progression within the first 6 months of treatment. Moreover, two of these trials evaluated front-line treatment in the subgroup of patients with wild-type *RAS* mCRC.^[@CR8],[@CR9]^ The randomised phase 3, PRODIGE 9 study, aimed to assess the tumour control duration with bevacizumab maintenance or observation after irinotecan-based IC combined with bevacizumab.^[@CR11]^ Two other recent trials randomised patients without progression after IC.^[@CR12],[@CR13]^ As the randomisation was performed prior to the front-line treatment whatever the *RAS* status, analysis of the PRODIGE 9 trial allows the determination of prognostic factors in all patients with mCRC.

The purpose of this ancillary study of the PRODIGE 9 trial is to determine the prognostic factors for early progression during IC, and during the first CFI in the subgroup of patients without progression of the disease after IC.

Methods {#Sec2}
=======

PRODIGE 9 was an open-label, randomised, multicentre, phase 3 study conducted by the Fédération Francophone de Cancérologie Digestive (FFCD) and the PRODIGE intergroup in 66 French centres comparing IC with FOLFIRI plus bevacizumab followed by bevacizumab monotherapy (maintenance arm) or the same induction treatment followed by observation.^[@CR11]^ The IC was planned for 12 cycles (6 months) after randomisation. The main eligible criteria were histologically proven, non-resectable mCRC, WHO status ≤ 2, life expectancy ≥ 3 months, absence of previous chemotherapy or anti-angiogenic therapy for metastatic disease. The primary endpoint was the tumour control duration defined as the time elapsed between randomisation and tumour progression during a chemotherapy sequence. There were no significant differences between the two arms not only for the primary endpoint but also for the median duration of the first CFI.^[@CR14]^

Progression or death during IC was considered as the event for prognostic factor analysis of early progression during IC. Only patients without progression during induction chemotherapy who have entered in the CFI phase were analysed for the determination of prognostic factors related to the duration of the first CFI. Duration of the first CFI was defined as the time between the end of IC and the first reintroduction of chemotherapy whatever the regimen or death.

The following factors were evaluated for early progression during IC, and for early (\<3 months) or late progression (\>5 months) during the first CFI: treatment arm, sex, age, WHO performance status (PS), resection of primary tumour, number of metastatic sites, primary localisation, leukocytes, platelets, alkaline phosphatase, carcinoembryonic antigen (CEA) level, tumour *KRAS* status, tumour *BRAF* status (tumour with *KRAS* mutation was considered as *BRAF* wild type) and decrease in CEA \>50% at 2 months. Tumour response at the end of induction chemotherapy and early shrinkage at first evaluation were evaluated only for CFI duration. A logistic model was used to identify the prognostic factors. A significance level of 0.2 was required to enter into the final univariate model and to stay in the multivariate model. We have considered as interesting a factor with a level of 0.10 in the multivariate model.

Results {#Sec3}
=======

Between March 2010 and July 2013, the PRODIGE 9 trial enrolled 494 patients. Among them, six patients withdrew their consent (3) or were never treated (3); thus, the modified intent-to-treat population was 488 patients randomly assigned to either FOLFIRI plus bevacizumab IC followed by bevacizumab maintenance (*n* = 245), or to the same IC followed by observation during CFI (*n* = 243).

Disease progression or death during IC occurred in 85 (17.4%) patients. Among the 403 patients who have no progression or death during IC, 59 had no CFI due to investigator decision, toxicities or other reasons. Among the remaining 344 patients, 128 (37.2%) patients had a CFI \<3 months, 100 (29%) patients had a CFI between 3 and 5 months and 116 (33.7%) patients had a CFI \>5 months (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart.

Factors associated with progression during induction chemotherapy {#Sec4}
-----------------------------------------------------------------

Baseline characteristics of patients with and without tumour progression during IC are presented in Supplementary Table [S1](#MOESM1){ref-type="media"}. Univariate analysis revealed that baseline WHO performance status of 2, baseline leukocytes \>10 × 10^9^/L, baseline CEA upper limit of normal and stable or increasing CEA at 2 months after the beginning of IC were associated with a higher risk of progression during IC (Table [1](#Tab1){ref-type="table"}). In multivariate analysis, baseline leukocytes \>10 × 10^9^/L and stable or increasing CEA at 2 months were independent factors associated with progression during IC (Table [2](#Tab2){ref-type="table"}). The ratio of neutrophils/leukocytes was also explored, but adds no additional result to the leukocyte count alone (data not shown).Table 1Univariate analysis of characteristics associated with a progression during induction chemotherapy.CharacteristicsOR for progression\[95% CI\], *p* valueGenderFemale vs male1.28\[0.79--2.07\], *p* = 0.31Age≤65 vs \>651.16\[0.73--1.86\], *p* = 0.52WHO performance status1 vs 02 vs 01.593.79\[0.95--2.65\], *p* = 0.43\[1.78--8.09\], *p* = 0.002Primary tumour resectedNo vs yes1.26\[0.79--2.02\], *p* = 0.33Number of metastatic sites\>1 vs 11.16\[0.71--1.88\], *p* = 0.55Primary locationRight colon vs left colon or rectum0.87\[0.62--1.31\], *p* = 0.41Baseline leukocytes\>10 × 10^9^/L vs ≤10 × 10^9^/L1.91\[1.16--3.15\], *p* = 0.01Baseline platelet≥400 × 10^9^/L vs \<400 × 10^9^/L1.68\[0.92--3.08\], *p* = 0.09Baseline alkaline phosphatase\>300 vs ≤300 U/L1.39\[0.79--2.44\], *p* = 0.25Baseline CEA\>ULN vs normal2.46\[0.86--7.09\], *p* = 0.10Two months CEA vs baseline CEAStable or increase vs decrease \>50%3.00\[1.44--6.23\], *p* = 0.01Tumour *KRAS*Mutated vs wild type1.12\[0.65--1.92\], *p* = 0.70Tumour *BRAF*Mutated vs wild type1.30\[0.42--4.04\], *p* = 0.65*CEA* carcinoembryonic antigen, *ULN* upper limit of normal.Table 2Multivariate analysis of characteristics associated with a progression during induction chemotherapy.Characteristics*N* = 363OR for progression\[95% CI\], *p* valueWHO performance status1 vs 02 vs 01.181.65\[0.61--2.27\], *p* = 0.80\[0.57--4.75\], *p* = 0.40Baseline leukocytes\>10 × 10^9^/L vs ≤10 × 10^9^/L1.98\[1.02--3.8\], *p* = 0.04Baseline CEA\>ULN vs normal2.84\[0.93--8.70\], *p* = 0.07Two months CEA vs baseline CEAStable or increase vs decrease \>50%3.61\[1.68--7.75\], *p* = 0.01Baseline platelet≥400 × 10^9^/L vs \<400 × 10^9^/L1.09\[0.55--2.14\], *p* = 0.81*CEA* carcinoembryonic antigen, *ULN* upper limit of normal.

Factors associated with short duration of chemotherapy-free interval {#Sec5}
--------------------------------------------------------------------

Baseline characteristics of patients according to the CFI duration are presented in Supplementary Table [S2](#MOESM1){ref-type="media"}. Univariate analysis revealed that male gender, WHO performance status of 1 or 2, unresected primary tumour, right colon primary, baseline leukocytes \>10 × 10^9^/L, baseline platelet \>400 × 10^9^/L, baseline alkaline phosphatase \>300 IU/L, baseline CEA upper limit of normal, *BRAF* mutation and no tumour response at 2 months were associated with a short duration of CFI (Table [3](#Tab3){ref-type="table"}). In multivariate analysis, male gender and no tumour response at 2 months were associated with a short CFI (Table [4](#Tab4){ref-type="table"}). The multivariate analysis performed in the subgroup of patients with *BRAF* V600E mutation status available revealed that *BRAF*- mutated status was the only factor associated with a short CFI (OR = 4.59 \[0.95; 22.26\], *p* = 0.058).Table 3Univariate analysis of characteristics associated with a short duration (\<3 months) of chemotherapy-free interval.CharacteristicsOR for progression\[95% CI\], *p* valueTreatment armMaintenance vs observation1.20\[0.81--1.77\], *p* = 0.17GenderMale vs female1.33\[0.88--2.02\], *p* = 0.17Age≤65 vs \>651.10\[0.74--1.62\], *p* = 0.64WHO performance status1 vs 02 vs 01.357.10\[0.90--2.02\], *p* = 0.09\[2.16--23.35\], *p* = 0.001Primary tumour resectedNo vs yes1.74\[1.16--2.60\], *p* = 0.007The number of metastatic sites\>1 vs 11.08\[0.72--1.60\], *p* = 0.72Primary locationRight colon vs left colon or rectum1.49\[0.89--2.49\], *p* = 0.13Baseline leukocytes\>10 × 10^9^/L vs ≤10 × 10^9^/L2.13\[1.32--3.44\], *p* = 0.002Baseline platelets≥400 × 10^9^/L vs \<400 × 10^9^/L1.77\[1.06--2.95\], *p* = 0.03Baseline alkaline phosphatase\>300 vs ≤3003.54\[2.04--6.13\], *p* \< 0.0001Baseline CEA\>ULN vs normal1.82\[1.02--3.22\], *p* = 0.04Two months CEA vs baseline CEAStable or increase vs decrease \>50%1.15\[0.64--2.11\], *p* = 0.63Tumour *KRAS*Mutated vs wild type1.06\[0.68--1.64\], *p* = 0.81Tumour *BRAF*Mutated vs wild type6.19\[1.74--22.05\], *p* = 0.005Tumour evaluation at 2 monthsStable disease vs complete or partial response1.96\[1.29--2.99\], *p* = 0.002Tumour evaluation at 6 monthsStable disease vs complete or partial response1.42\[0.92--2.19\], *p* = 0.12*CEA* carcinoembryonic antigen, *ULN* upper limit of normal.Table 4Multivariate analysis of characteristics associated with a short duration (\< 3 months) of chemotherapy-free interval.Characteristics*N* = 172OR for progression\[95% CI\], *p* valueGenderMale vs female1.72\[0.92--3.25\], *p* = 0.09WHO performance status1 vs 02 vs 01.333.38\[0.72--2.44\], *p* = 0.36\[0.48--23.78\], *p* = 0.22Primary tumour resectedNo vs yes1.57\[0.84--2.98\], *p* = 0.16Primary locationRight colon vs left colon or rectum1.35\[0.70--2.62\], *p* = 0.37Baseline leukocytes\>10 × 10^9^/L vs ≤10 × 10^9^/L0.95\[0.43--2.08\], *p* = 0.89Baseline alkaline phosphatase\>300 vs ≤300 U/L1.35\[0.54--3.37\], *p* = 0.53Baseline CEA\>ULN vs normal1.94\[0.80--4.71\], *p* = 0.14Baseline platelet≥400 × 10^9^/L vs \<400 × 10^9^/L1.32\[0.59--2.96\], *p* = 0.50Tumour evaluation at 2 monthsStable disease vs complete or partial response1.90\[0.96--3.76\], *p* = 0.07Tumour evaluation at 6 monthsStable disease vs complete or partial response1.33\[0.69--2.56\], *p* = 0.39*CEA* carcinoembryonic antigen, *ULN* upper limit of normal.

Discussion {#Sec6}
==========

Our results showed that baseline-elevated leukocytes and stable or increasing CEA at 2 months were independent factors associated with progression during IC. In this study, we have investigated prognostic factors for early progression within the first 6 months of chemotherapy. In the PRODIGE 9 trial, the independent prognostic factors associated with a shorter PFS were PS 2 and *BRAF* mutation.^[@CR14]^ *BRAF* mutation was also reported as a prognostic factor for shorter PFS in previous trials^[@CR10],[@CR15]^ after both doublet and triplet chemotherapy combined with bevacizumab. Nevertheless, the *BRAF* mutation was not found as a prognostic factor of early progression in our study. Baseline CEA and early CEA variation during chemotherapy were already reported as associated with PFS or OS.^[@CR16],[@CR17]^ Interestingly, the prognostic value of baseline CEA was reported in patients treated with FOLFIRI plus bevacizumab, but not with FOLFIRI plus cetuximab.^[@CR18]^ In this study, the lack of decrease in CEA at 2 months was associated with an early progression, and potentially should be considered in order to intensify chemotherapy. Circulating DNA is described as another early marker of chemotherapy efficacy.^[@CR19]^ Unfortunately, this biomarker was not collected in our study. CEA and circulating DNA monitoring have both advantages and limitations. CEA is easy to perform with low cost, but some tumours do not produce even CEA, and could not be evaluated with this marker. Circulating DNA requires specific technology, provides additional cost and needs further evaluation in a metastatic setting. It would be worthwhile to compare the predictive value of both markers. Elevated baseline leukocytes are prognostic of an early progression in this study. The Köhne criteria include this parameter as a prognostic factor for OS.^[@CR20]^ However, elevated baseline leukocytes were not a prognostic factor for PFS on the main analysis of PRODIGE 9 trial.^[@CR14]^ Thus, according to our results, both parameters, the lack of the CEA decrease level and the elevated baseline leukocytes as prognostic factors for early progression, should be confirmed in another series. Other prognostic factors for early progression could also be integrated as radiomic evaluation^[@CR21]^ or biological markers beyond *BRAF* mutation as consensual molecular classification.^[@CR22]^

Male gender and no tumour response at 2 months according to RECIST 1.1 criteria were found to be prognostic for a short first CFI. Previous studies have assessed prognostic factors for CFI or maintenance treatment. In the COIN trial that evaluated IC continuation compared with CFI, baseline thrombocytosis was associated with a short CFI.^[@CR23]^ In our study, baseline thrombocytosis was associated with short CFI in univariate analysis but not in multivariate analysis, suggesting confounding factors or a lack of statistical power. In the CAIRO 3 trial, tumour response and synchronous metastasis were associated with a longer PFS in the maintenance arm with capecitabine plus bevacizumab.^[@CR12]^ Patients with stable disease at the first evaluation have a shorter CFI, suggesting that CFI is not appropriate for those patients. In a pooled analysis of CAIRO 3 and AIO 0207 trials, female gender, synchronous-resected metastasis and *BRAF* mutation were associated with a longer OS if maintenance chemotherapy is performed compared with observation.^[@CR24]^ It must be pointed out that in our study, *BRAF* mutation was the strongest negative predictor for CFI in univariate and in multivariate analysis in the subgroup of patients with *BRAF* status determination. In regard to these and our results, it seems reasonable to recommend a maintenance chemotherapy rather than CFI in patients with *BRAF*-mutated tumour.

Our study has several limitations. First, it is a post hoc unplanned analysis, a prospective trial comparing treatment adaptation according to prognostic factors with no adaptation, which could only demonstrate the validity of the concept. A switch to oxaliplatin and/or to anti-EGFR in the case of *RAS* wild-type tumour, or to other targeted therapies in the case of *BRAF* mutant tumour according to recent results,^[@CR25]^ could be evaluated if the signal of early progression during induction is observed, and maintenance chemotherapy as 5FU or capecitabine plus bevacizumab combination could be compared with CFI if it was a signal of short CFI. In the subgroup of patients with tumour *BRAF* mutation, it would be of interest to compare continuous induction chemotherapy with capecitabine plus bevacizumab chemotherapy or encorafenib plus cetuximab. Second, all the patients received irinotecan and bevacizumab treatment; thus, whether our findings could be extended to first-line oxaliplatin and/or anti-EGFR-based chemotherapy remains to be demonstrated.

In conclusion, early progression may be anticipated in the case of elevated leukocytes at baseline, and no CEA decrease at first evaluation. Further study should be performed to evaluate other radiologic or biologic predictors. Caution should be taken before performing a CFI without maintenance treatment in patients with *BRAF*-mutated tumour or lack of tumour response at first evaluation. Our results would help making decisions for patients who prefer a complete CFI rather than maintenance chemotherapy. Further studies are needed in a larger number of patients to confirm these results and add eventually other prognostic factors.
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